ES19.01 Benefits and Limitations of Systemic Therapy for Malignant Pleural Effusion
نویسندگان
چکیده
منابع مشابه
Current and future therapy for malignant pleural effusion.
Several options are available for treatment of malignant pleural effusions in patients with non-small-cell lung cancer. Repeat thoracentesis may be appropriate for the patient with limited survival and a slowly recurrent effusion. Pleurodesis with a sclerosing agent administered via a chest tube is the most widely used therapy, though controversy exists as to which drug produces the best result...
متن کاملTh1 and Th2 Cytokine Profiles in Malignant Pleural Effusion
Background: The alteration of Th1 and Th2 cytokine levels is the subject of controversy in pleural effusions caused by malignancy, a situation that favors a Th2 immune response. Objective: To examine the different levels of IL-4 and IL-10 (Th2 cytokines), and IL-2 and interferon-γ (IFN-γ) (Th1 cytokines) in malignant and non-malignant pleural effusions. Method: The cytokine levels in pleural fl...
متن کاملMalignant pleural effusion.
Malignant pleural effusion (MPE) refers to the presence of neoplastic cells in the pleural fluid. Approximately 40 000 people per year in the UK are affected by MPE and it is associated with significant morbidity and an overall poor prognosis. Management should be prompt and care plans should be individualized and involve a multidisciplinary team of healthcare professionals. This article review...
متن کاملBest current therapy for patients with malignant pleural effusion.
slurry or thoracoscopic talc poudrage pleurodesis. Furthermore, it remains unclear whether spontaneous pleurodesis with TPC prolongs life. In survivors to 14 weeks, the mean time to pleurodesis was 54 days. One coauthor’s earlier study revealed that those with TPC who had spontaneous pleurodesis lived over 3 times as long as those who did not have pleurodesis [2] . If pleurodesis by itself prol...
متن کاملMalignant pleural effusion.
Kathleen Shuey, MS, RN, AOCN®, APRN, BC, is an associate director at US Oncology in Houston, TX, and Yvette Payne, MSN, MBA, RN, APN, is an associate director of Clinical Affairs–Oncology at Ortho Biotech Clinical Affairs, LLC, in Tampa, FL. (Mention of specifi c products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2019
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.08.152